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Objectives: Venous thromboembolism (VTE) is a frequent but preventable compli-
cation in hospitalized patients. The objective of this population-based simulation 
was to estimate, for Saudi Arabia and using a British (NICE) model, the cost-effi-
ciency of partial versus complete thromboprophylaxis of hospitalized adult patients 
at medium-to-very-high (M2VH) -VTE risk. MethOds: Simulation including all 2012 
Saudi adult medical (n= 2,129,866) and surgical (n= 964,033) hospital admissions, 
expressed in Saudi riyals (SAR), using three scenarios based on published real-
world thromboprophylaxis studies: (1) international study and (2) Saudi subsample 
thereof (Cohen et al, Lancet 2008), and (3) Middle-Eastern study (Mokhtari et al, J 
Thromb Haemost 2011). Variables included rates for: high bleeding risk (mechanical 
versus pharmacoprophylaxis); major bleeding episode (MBE) secondary to pharma-
coprophylaxis; deep vein thrombosis (DVT; pulmonary embolism (PE); and 12-month 
DVT/PE readmission following such discharge diagnosis. Costs considered were: 
thromboprophylaxis; management of MBE, DVT, PE; and 12-month DVT/PE read-
mission. Results: Scenario (1): total costs for partial and complete prophylaxis 
were SAR631,462,830 and SAR508,957,517 for a complete-over-partial cost-avoidance 
by 24.1% of SAR122,505,313/year (SAR92.14 per patient and SAR167.83 per patient 
at VTE risk). Scenario (2): total costs for partial and complete prophylaxis were 
SAR712,441,824 and SAR600,483,584 for a complete-over-partial cost-avoidance 
by 18.6% of SAR111,958,239/year (SAR77.35 per patient and SAR127.58 per patient 
at VTE risk). Scenario (3): total costs for partial and complete prophylaxis were 
SAR749,939,936 and SAR647,300,590 for a complete-over-partial cost-avoidance by 
15.9% of SAR102,639,346/year (SAR62.77 per patient and SAR97.84 per patient at VTE 
risk). cOnclusiOns: In this population-based cost-efficiency simulation for Saudi 
Arabia, thromboprophylaxis of all admitted M2VH-VTE risk versus partial methods 
is associated with significant cost savings per year. Considering the associated 
reductions in DVT, PE, and readmissions, even under increased pharmacoprophy-
laxis-related MBE risk and costs, complete thromboprophylaxis of (M2VH) -VTE risk 
patients achieves the Institute for Healthcare Improvement Triple Aim of better care, 
better patient outcomes, and reduced costs.
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CoSt minimization analYSiS of aCtiVated ProthromBin ComPlex 
ConCentrate (aPCC) ComPared to reComBinant faCtor Viia (rfViia) for 
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Objectives: Approximately 15-35% of patients with hemophilia A develop inhibi-
tory antibodies to factor VIII. There are currently two bypassing agents to treat 
inhibitor patients in the case of bleeding episodes (BE) and preemptively before 
and during major surgeries. Both APCC and rFVIIa demonstrated similar efficacy 
and safety results. Our aim was to compare the costs of bypass strategy based on 
APCC or rFVIIa while we included only drug acquisition costs, and from them we 
derived costs of bleeding episodes and surgery costs in Hungary, Slovakia, Slovenia 
and Serbia. MethOds: For the purpose of cost comparison, we developed a model 
using cost-minimization approach which included only the costs of APCC or rFVIIa. 
We assessed the cost differences for two basic scenarios - patients with bleeding 
episodes and patients undergoing major surgeries. The doses used in model were: 
i) BE APCC 62.5 U/kg, ii) surgery APCC 85 U/kg, iii) BE and surgery rFVIIa 90 μ g/kg. 
The doses are based on the SmPCs (middle of given dose intervals) and published 
literature (in the case of APCC used in surgery which is administered in higher doses 
in clinical practice compared to declaration in SmPC). Results: In the scenario 
of bleeding episodes, the use of APCC instead of rFVIIa brings the potential sav-
ings € 4,596-8,704; € 5,135-9,347; € 5,738-10,807; € 4,369-8,527 respectively in Hungary, 
Slovakia, Slovenia and Serbia (depending on the dosing scheme). While using APCC 
during major surgeries, the savings are equal to € 157,159 (if compared to rFVIIa 
therapy) and € 15,616 (if compared to the combination therapy of APCC and rFVIIa) 
in Hungary; € 180,653 and € 16,558 in Slovakia; € 196,965 and € 19,362 in Slovenia; 
and € 145,979 and € 15,422 in Serbia. cOnclusiOns: The potential savings by using 
APCC instead of rFVIIa are significant for health care systems, APCC thus indirectly 
enables more treated patients for the same health care costs consumption.
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Objectives: Perform a full economic evaluation of cost minimization of the use 
of Methadone versus oxycodone (extended release), buprenorphine (transdermal 
patches), fentanyl (transdermal patches) and hydromorphone in opioid rotation 
for patients with acute severe pain secondary to cancer and chronic type as rota-
tion option in Mexico, from the point of view of public health. MethOds: A sys-
tematic literature review was conducted to identify articles and extract data of 
safety and efficacy and compare the available alternatives: methadone, oxycodone, 
buprenorphine (PT), fentanyl (PT) and hydromorphone. Based on the results of this 
systematic review was identified that 5 alternatives presented safety and efficacy 
profiles without significant differences. Economic evaluation corresponded to a 
cost minimization, the analysis was performed with three subgroups with rotation 
of opioids, each subgroup received a certain amount of morphine (80mg, 160mg, 
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Objectives: To assess the incremental cost-utility ratio (ICUR) of bosutinib for CML 
as a third-line (3L) treatment for chronic phase (CP) Philadelphia chromosome-
positive (Ph+) patients in Portugal compared to hydroxycarbamide, in the societal 
perspective. MethOds: A survival analysis model was adapted to the Portuguese 
setting. Bosutinib overall survival was based on Study 200, an open-label phase I/
II single-arm study of Ph+ CML patients. Overall survival with hydroxycarbamide 
and time spent in the accelerated and blastic phases, that are assumed to be inde-
pendent of treatment, were estimated by an expert panel of five Portuguese hae-
matologists. Resource consumption was elicited by this expert panel, being unit 
costs based on Portuguese official sources. Utility values were adapted from the IRIS 
study. A 5% discount rate was applied to both costs and consequences on a 50-year 
time horizon. Results: The use of bosutinib allows an increase of 4.1 life years 
(LY) and 3.5 quality adjusted life years (QALY), being associated to an additional 
cost of 88,319€ . Consequently, cost per LY is 21,465€ and cost per QALY is 25,252€ . 
Sensitivity analysis shows that results are mainly driven by survival time gained 
with bosutinib. cOnclusiOns: Bosutinib for CML 3L treatment for CP patients 
in Portugal represents a substantial added benefit relative to hydroxycarbamide 
although with added costs per LY and per QALY. These ratios are generally accepted 
in Portugal, both below 30,000€ willingness to pay threshold.
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Objectives: To assess the cost-effectiveness of romiplostim in the treatment 
of adult patients with ITP in the Czech Republic, in comparison with the medi-
cal standard of care (SoC) and eltrombopag. MethOds: A lifetime treatment 
sequence cost-utility Markov model was developed from the health care payer 
perspective. The model was based on the treatment sequences that reflect cur-
rent practice for ITP management and was driven by platelet response (platelet 
count ≥ 50x109/L), which determined effectiveness and progression along the treat-
ment pathway, need for rescue therapy and risk of bleeding. Costs were derived 
from reimbursement lists available in January 2013. Four scenarios were con-
ducted where romiplostim was compared with SoC with rituximab, SoC without 
rituximab, SoC without both rituximab and mycophenolate mofetil (MMF), and 
eltrombopag. Patients were evaluated by splenectomy status and for the combined 
population (CP). Results: Compared to SoC with rituximab, romiplostim was 
dominant in splenectomised patients and CP, with cost savings of 2,203,982CZK 
and 1,078,899CZK and gains of 1.58 and 1.81 quality-adjusted life-years (QALYs), 
respectively, and was cost-effective in non-splenectomised patients with an ICER 
of 44,107 CZK/QALY. Compared to eltrombopag, romiplostim was dominant in 
splenectomised patients and CP, with cost savings of 1,626,409CZK and 741,613CZK 
and gains of 1.12 and 1.21 QALYs, respectively, and was cost-effective in non-
splenectomised patients with an ICER of 74,266 CZK/QALY. Similar results were 
shown in the other two scenarios: romiplostim was dominant in splenectomised 
patients and CP compared to SoC without rituximab and SoC without both rituxi-
mab and MMF, and was cost-effective in non-splenectomised patients with ICERs 
of 51,011CZK/QALY (SoC without rituximab) and 41,192CZK/QALY (SoC without 
rituximab and MMF). cOnclusiOns: Romiplostim was less costly with higher 
QALY gain compared to SoC and eltrombopag in splenectomised patients and CP. 
Romiplostim was cost-effective with ICERs between 41,000 and 74,000CZK/QALY 
in all non-splenectomised populations in all four scenarios.
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Objectives: To evaluate the cost-effectiveness of celecoxib compared with loxo-
profen for the treatment of patients with chronic pain caused by osteoarthritis, 
rheumatoid arthritis and low back pain in Japan. MethOds: Using the Markov 
model, long-term simulations were conducted with a 3-month Markov cycle for 
each regimen of celecoxib vs. loxoprofen in the perspective of Japanese health 
care payers. The direct medical costs and quality-adjusted life years (QALYs) were 
estimated as outcome measures throughout the lifetime of patients. The base 
case population was aged 57 years which was the weighted mean age from the 
cited literature. All the costs were expressed as of March 2014, and annual dis-
count rates of 2% were applied for both costs and health benefits. Results: The 
incremental effectiveness of celecoxib compared with loxoprofen was 0.024 QALY 
while the incremental cost was JPY 73,785 (USD 716, USD 1 = JPY 103), indicating 
the incremental cost-effectiveness ratio (ICER) was JPY 3,131,480 (USD 30,403) per 
QALY gained. Sensitivity analyses identified two factors substantially sensitive to 
ICER: 1) decrease in efficacy of celecoxib in the recurrence of symptomatic ulcer, 
and 2) increase in utility of the primary disease that causes chronic pain while the 
administration of the drug halts. The literature review, however, supported that 
both of those sensitive cases are not so much likely to happen. cOnclusiOns: 
Celecoxib was considered cost-effective compared with loxoprofen in patients 
with chronic pain in Japan.
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patients presented an overall clinical improvement of ≥ 20%, ≥ 50% and ≥ 80%. These 
improvements were associated with a reduction of steroid use (75% of patients 
on steroids at belimumab-initiation decreased mean dose from 14.8 to 6.8mg/day; 
p< 0.001) and HRU between the pre/post index periods: emergency-room visits 1.65 
to 0.41; p= 0.001; unscheduled visits to treating-physician 1.02 to 0.03; p< 0.001, 
visits to other specialists (1.64 to 1.06; p= 0.017) and antibody tests (7.78 to 7.53; 
p= 0.47). An increase in HRU was observed for hematological and renal tests (3.14 to 
3.52; p= 0.045) and (5.95 to 6.59; p= 0.024), respectively. Working patients (39%) also 
showed a reduction in the LA days between the pre/post index periods (25.6 to 5.7 
days; p= 0.025). cOnclusiOns: Belimumab treatment yielded improved clinical 
outcomes and a reduction in HRU directly related with SLE management, as corti-
coid use. Mean number of LA days also showed a substantial reduction, especially 
important in SLE, mostly affecting young patients.
SYStemiC diSorderS/ConditionS – Patient-reported outcomes & Patient 
Preference Studies
PSY74
imPaCt of Patient ProgramS on adherenCe in inflammation and 
immunologY: a gloBal SYStematiC reVieW and meta-analYSiS of 
PuBliShed eVidenCe
Burudpakdee C.1, Khan Z.M.2, Gala S.1, Nanavaty M.1, Kaura S.2
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Objectives: Patient adherence is important for successful treatment in chronic 
conditions, including inflammation and immunology (I&I) diseases, to improve 
patient outcomes. Programs and interventions that aim at improving medica-
tion adherence play an essential role in optimizing care. This review and meta-
analysis assessed the effectiveness of different types of adherence programs in 
I&I. MethOds: A global systematic literature search was conducted and studies 
were identified from PubMed, conference proceedings, and grey literature. Selection 
criteria included studies of patient programs in I&I diseases published in English 
language between January 2008 and September 2013 that reported % of adherent 
patients. A meta-analysis was performed using a random effects model. Weights, 
odds ratios, 95% CI, and forest plots were developed for behavioral, informational, 
and combination interventions. Results: Of 29 studies screened, a total of 13 stud-
ies were eligible for inclusion in the meta-analysis. Seven studies were in patients 
with osteoporosis, 4 in ulcerative colitis, 1 in childhood-onset systemic lupus ery-
thematosus, and 1 in rheumatoid arthritis / psoriasis. Overall, patient programs 
increased adherence (OR = 2.48, 95% CI = 1.68 - 3.64, P < 0.00001) as compared 
to standard of care or no intervention. Combination interventions that used both 
informational and behavioral strategies were superior in increasing adherence (OR 
= 3.68, 95% CI = 2.20 - 6.16, P < 0.00001) compared to interventions using solely a 
behavioral strategy (OR = 1.85, 95% CI = 1.00 - 3.45, P = 0.05) or only an informational 
strategy (OR = 2.16, 95% CI = 1.36 - 3.44, P = 0.001). cOnclusiOns: Patient programs 
and interventions can significantly improve adherence in I&I diseases as compared 
to standard of care or no intervention. Programs employing a multimodal approach 
are more effective in improving adherence than either informational or behavioral 
strategies alone. This in turn may improve patient outcomes.
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1The University of Texas at Austin, Austin, TX, USA, 2Baylor College of Medicine/Texas Children’s 
Hospital, Houston, TX, USA
Objectives: The American College of Chest Physicians Guideline recommends anti-
coagulant therapy for at least three months in children with venous thromboembo-
lism. The objectives of the study were to evaluate the medication utilization patterns, 
and the predictors of adherence to anticoagulant therapy in the pediatric popula-
tion. MethOds: Texas Medicaid medical and prescription claims from June 01, 
2007 to September 31, 2012 were extracted for children (< 18 years) hospitalized 
for Pulmonary Embolism (PE) or Deep Vein Thrombosis (DVT). The index date was 
defined as the date of the first prescription of an anticoagulant warfarin (oral) 
and/or enoxaparin (injectable) given within 14 days after discharge from hospi-
talization. Patients hospitalized for atrial fibrillation, air/fat embolism, bleeding/
coagulation disorder within 90 days of discharge were excluded. Proportion of 
days covered (PDC≥ 80% vs. < 80%) was used to assess adherence to anticoagulants 
while controlling for demographics, cause of hospitalization, history of NSAID use, 
anticoagulant use, malignancy, drug type, and Charlson comorbidity index (CCI). A 
multivariate logistic regression analysis was used. Results: The patients (n= 57) 
had a mean (±SD) age of 14.1 (±4.9) years, were primarily female (54.4%), African 
American (61.4%), enoxaparin users (54.4%), and had a mean (±SD) CCI of 19.7 (±39.4). 
The mean (±SD) adherence rates for warfarin and enoxaparin were 85.6% (±22.3%) 
and 78.2% (±22.7%), respectively. 66.7% were adherent (PDC≥ 80%) to anticoagulant 
therapy. The median (Mean±SD) persistence with anticoagulant therapy was 84.6 
(71.9±33.3) days. Logistic regression showed that increasing age was significantly 
associated with adherence to anticoagulant therapy (Odds Ratio= 1.3, p= 0.0158), 
after controlling for covariates. cOnclusiOns: Nearly one third of the pediatric 
patients on anticoagulant therapy after discharge from hospitalization with PE or 
DVT were non-adherent. Further research is needed to underline the factors respon-
sible for non-adherence in pediatric patients.
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neW oBSerVer-rePorted outComeS to meaSure treatment 
SatiSfaCtion, ComPlianCe, PalataBilitY, and gi SYmPtomS for 
PatientS needing iron-Chelation theraPY
Lasch K.1, Horodniceanu E.G.2, Carter J.A.2, Dhatt H.2, Bal V.3, Côté I.3, Constantinovici N.4, 
Herranz R.M.4, Malet I.4
480 mg respectively) before rotation the number of milligrams of each opioid was 
calculated based on equianalgesic tables using only direct medical costs, further 
a deterministic sensitivity analysis was performed. Results: The results dem-
onstrate that methadone (Amidone ®) generates average savings per patient of 
$ 84.37 to $ 5,817.00 compared to oxycodone, buprenorphine (PT), fentanyl (PT) and 
hydromorphone in the three subgroups analyzed, the sensitivity analysis shows 
that methadone remains a cost-saving option. cOnclusiOns: Using Methadone 
(Amidone ®) is a cost-saving option for patients with acute and chronic severe pain 
secondary to cancer in Mexico, from the institutional point of view.
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real-World CoSt-utilitY eValuation of multiPle mYeloma 
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Objectives: Multiple myeloma (MM) is an incurable disease with an incidence 
of 4-7 new cases by 100.000 people. In the setting of the study, 28% of the yearly 
25 news cases of MM are candidates to autologous stem cell transplant (ASCT). 
Because of the lack of real-world economic studies, authors sought to describe 
the cost per quality-adjusted-life-year (QALY) of the MM treatment in a group of 
transplanted patients. MethOds: An observational retrospective study was per-
formed and included detailed clinical data from a transplanted cohort of patients 
with MM. All patients received bortezomib based treatments. Costs were evaluated 
from the payer’s perspective and included total drug costs and hospital admission 
costs. QALYs values were obtained from the CEA Registry of Tufts University. Four 
health states were considered: complete response (CR), partial response, stability 
and progressive disease. Time between state transitions was used to calculate QALYs 
for each patient. Results: The study included 17 patients with a mean age of 61,2 
years; 12 of them (Group 1) were followed during 2,77±0,24 years and 5 (Group 2) dur-
ing 1,6±0,19 years. Global complete response rate one year after ASCT was 8/17 (47%) 
and dropped to 5/12 (41,6%) at two years. For the whole cohort the median of QALY’s 
cost was 56.198€ (IQ range 36.391-70.339). For patients with CR one year after ASCT, 
the median of QALY’s cost was 46.358€ (IQ range 36.299-67.537). For all other patients 
the median of QALY’s cost was 56.676€ (IQ range 39.114-73.613). For Group 1 patients, 
the median of QALY’s cost was 51.278€ (IQ range 36.345-73.613). cOnclusiOns: 
These results reveal that the actual costs of MM treatment using protocols that 
include bortezomib are above the 30.000-50.000€ threshold generally admitted in 
cost-effectiveness studies.
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orPhan drug PriCing in franCe: influenCe of main faCtorS
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Objectives: Orphan drugs (OD) require considerable expenditures, which causes 
difficulties in their market access. For several years, the price of these new therapies 
has often been criticized and considered as too high. However few studies about 
OD pricing mechanisms are available. The aim of the paper is to highlight the main 
factors that influence OD pricing in France. MethOds: We collected public prices 
of 37 products designated as OD and approved by the European Medicines Agency 
until January 2014. Given that an OD can have several indications, our database 
contains 49 observations. For each observation, we calculated the ex-factory price 
without tax (defined per daily dose) defined by summary products characteristics. 
We also collected different characteristics of these products: improvement in actual 
clinical benefit (IACB), actual clinical benefit (ACB), number of OD indications, 
number of comparators drugs, number of competing orphan drugs, therapeutic 
use, target population, inclusion on the list of medicines reimbursed by National 
Health Insurance. Ordinary least squares are used to analyse the determinants of 
OD prices. Results: The distribution of OD prices is very heterogeneous, with a 
minimum of 2.34 euros and a maximum of 2882.08 euros. The average (SD) price 
is 380.675 euros (687.414). Our main results are that OD prices are significantly 
lower for OD that do not improve actual clinical benefit (-136%, p= 0.024), for OD 
with only one orphan indication (-80%, p= 0.047), and for OD with a high target 
population (-251%, p= 0.000). cOnclusiOns: There is a need to understand OD 
pricing mechanisms. Our study shows that innovation and research efforts are 
encouraged by pricing policy.
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Objectives: To analyze the health resource utilization (HRU) and labour absentee-
ism (LA) in Systemic Lupus Erythematosus (SLE) patients treated with belimumab 
in the Spanish clinical setting. MethOds: OBSERVE is a multicenter retrospective 
medical chart-review study. Twenty-five rheumatologists from Spanish hospitals 
with > 10 SLE patients annually and > 5-years of practice experience identified adult 
SLE patients who had received 6-months of belimumab treatment. In the 6-months 
pre- and 6-months post-index periods physicians assessed: demographics, comor-
bidities, SLE disease characteristics, treatment clinical outcomes, HRU and LA data. 
Index-date is the date of the first infusion. OBSERVE primary endpoint was overall 
clinical response per physician judgment. Statistical analyses included appropri-
ate tests for paired-samples (parametric/ non-parametric). Two-way P-values 0.05 
were considered statistically significant. Results: A total of 64 patients were eli-
gible for analysis: mean age 42.7±12 years; female 89%; hypocomplementemia 70% 
and high anti-dsDNA 69%. After receiving 6-months therapy, 72%, 52% & 27% of 
